Diagnosis and treatment of non-small cell lung cancer (NSCLC) harboring MET Ex14 skipping: have we met the desired drug?

Transl Lung Cancer Res. 2024 Jun 30;13(6):1438-1443. doi: 10.21037/tlcr-24-93. Epub 2024 Jun 14.

Author

Affiliation

¹ Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

No abstract available

Keywords: MET; Non-small cell lung cancer (NSCLC); VISION; tepotinib.

Publication types

Editorial
Comment